Ben Sasse talks about Right to Try Act with dad battling glioblastoma

Key Concepts

• Right to Try Act: Federal legislation designed to allow terminally ill patients access to experimental treatments that have passed Phase I clinical trials but have not yet received full FDA approval.
• Glioblastoma: An aggressive type of cancer that can occur in the brain or spinal cord.
• Optune: A non-invasive, wearable medical device that uses Tumor Treating Fields (TTFields) to disrupt cancer cell division.
• Targeted Cancer Therapy (Signal Jamming): A therapeutic approach that inhibits specific molecular signals (often driven by defective genes) that cause cancer cells to proliferate uncontrollably, rather than using systemic chemotherapy.
• FDA Bureaucracy: The regulatory framework governing drug approval, which the speakers argue can be overly restrictive, limiting patient access to life-saving experimental interventions.

1. Main Topics and Key Points

The discussion centers on the tension between government regulation and individual patient autonomy regarding access to experimental medical treatments.

• Patient Advocacy: Mike Hugo, a glioblastoma survivor, highlights the disparity between the success of his clinical trial (using Optune) and the inability of other patients to access similar treatments due to regulatory hurdles.
• Regulatory Philosophy: Senator Ben Sasse argues for a "decentralized" approach to medicine, suggesting that patients and their doctors—not federal bureaucrats—should be the primary decision-makers regarding the risks of experimental drugs.
• The "Right to Try" Reality: While the Right to Try bill was signed into law, the speakers note that subsequent amendments made the process more restrictive than originally intended, effectively limiting its real-world application.

2. Real-World Applications and Case Studies

• Mike Hugo’s Case: Diagnosed with glioblastoma at age 33, Hugo participated in a clinical trial involving Optune. He is now four years post-diagnosis, defying the typical prognosis for his condition.
• Senator Sasse’s Treatment: The Senator discusses his own experience with a new cancer therapy. He describes the severe side effects (skin degradation, bleeding) as a trade-off for the drug’s efficacy in shrinking his tumor by 76%.
• Pancreatic Cancer Statistics: The Senator notes that 67,000 Americans are diagnosed with pancreatic cancer annually, with a very low survival rate, arguing that increased experimentation is the only viable path to improving these outcomes.

3. Methodologies: The "Jamming" Mechanism

The speakers explain a specific, non-systemic approach to cancer treatment:

• The Mechanism: Cancer is described as the result of defective genes sending constant "grow" signals to the body.
• The "Jammer" Concept: The experimental drug acts as a signal jammer. It does not fix the defective gene, but it prevents the "grow" signal from reaching the rest of the body, effectively halting tumor progression.
• Clinical Trial Success: The drug mentioned has shown a significant increase in life expectancy for patients, extending survival from a typical 6 months to 13 months and counting.

4. Key Arguments and Perspectives

• Risk Tolerance: Senator Sasse argues that patients facing terminal illnesses should have the agency to accept higher risks (and severe side effects) in exchange for the possibility of extended life.
• Population Health: The Senator posits that "more experiments are going to yield more great outcomes at a population health level." He advocates for "airing out" the FDA approval process to allow for faster innovation.
• The Role of Government: Sasse advocates for a middle ground: government should provide infrastructure for research but avoid "homogenizing" medical decisions through one-size-fits-all rules.

5. Notable Quotes

• Senator Sasse: "I’d rather decentralize a lot more of those decisions to individuals, patients, and their care providers rather than one-size-fits-all rules at the FDA."
• Senator Sasse: "There’s a difference between 13 months and four or six. Two daddy-daughter dances that no one said I would ever make."

6. Synthesis and Conclusion

The dialogue underscores a critical intersection of personal survival and public policy. The primary takeaway is that current regulatory frameworks, while intended to ensure safety, often create barriers that prevent terminally ill patients from accessing potentially life-extending experimental therapies. Both participants agree that shifting the decision-making power from federal agencies to patients and their physicians—and fostering an environment that encourages more frequent, accessible clinical experimentation—is essential for improving survival rates in aggressive cancers like glioblastoma and pancreatic cancer.